Jingchun Fan1, Fujian Song2, Max O Bachmann3. 1. Epidemiology and Evidence Based Medicine, School of Public Health, Gansu University of Chinese Medicine, Lanzhou City, Gansu Province, P.R. China; Public Health and Health Services Research, Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK. 2. Public Health and Health Services Research, Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK. Electronic address: fujian.song@uea.ac.uk. 3. Public Health and Health Services Research, Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK.
Abstract
OBJECTIVES: The aim of the article was to assess the appropriateness and rationales of subgroup analyses planned in protocols of randomized controlled trials and reported in subsequent corresponding trial publications. STUDY DESIGN AND SETTING: We searched PubMed to identify trial protocols published in journals during 2006-2017. From a total of 3,774 initially identified records, we included a random sample of 479 protocols and identified 280 trial publications corresponding to the included protocols. RESULTS: Subgroup analyses were specified in 19% of the protocols and reported in 21% of the trial publications. Of the 94 protocols with planned subgroup analyses, 32% mentioned testing for interaction, and only three considered statistical power. Subgroup analyses were not prespecified in 56% of the 59 trial publications with subgroup analyses. Subgroup analyses were stated as prespecified in nine trial publications, without support evidence from the corresponding protocols. Subgroup analyses were often reported insufficiently for assessing the consistency of subgroup effects across studies. Justifications for subgroup analyses were provided in only four trial protocols and seven trial publications. CONCLUSION: Inappropriate specification and reporting of subgroup analyses remain problematic in protocols and reports of randomized controlled trials. Justifications or rationales for subgroup analyses were only rarely provided in trial protocols and reports.
OBJECTIVES: The aim of the article was to assess the appropriateness and rationales of subgroup analyses planned in protocols of randomized controlled trials and reported in subsequent corresponding trial publications. STUDY DESIGN AND SETTING: We searched PubMed to identify trial protocols published in journals during 2006-2017. From a total of 3,774 initially identified records, we included a random sample of 479 protocols and identified 280 trial publications corresponding to the included protocols. RESULTS: Subgroup analyses were specified in 19% of the protocols and reported in 21% of the trial publications. Of the 94 protocols with planned subgroup analyses, 32% mentioned testing for interaction, and only three considered statistical power. Subgroup analyses were not prespecified in 56% of the 59 trial publications with subgroup analyses. Subgroup analyses were stated as prespecified in nine trial publications, without support evidence from the corresponding protocols. Subgroup analyses were often reported insufficiently for assessing the consistency of subgroup effects across studies. Justifications for subgroup analyses were provided in only four trial protocols and seven trial publications. CONCLUSION: Inappropriate specification and reporting of subgroup analyses remain problematic in protocols and reports of randomized controlled trials. Justifications or rationales for subgroup analyses were only rarely provided in trial protocols and reports.
Authors: Siyun Yang; Fan Li; Monique A Starks; Adrian F Hernandez; Robert J Mentz; Kingshuk R Choudhury Journal: Stat Med Date: 2020-08-21 Impact factor: 2.373
Authors: Rachel P Dreyer; Alyssa Berkowitz; Henry Klar Yaggi; Lynelle Schneeberg; Nilay D Shah; Lindsay Emanuel; Bhanuprakash Kolla; Molly Moore Jeffery; Mark Deeg; Keondae Ervin; Frances Thorndike; Joseph S Ross Journal: BMJ Open Date: 2022-08-08 Impact factor: 3.006
Authors: Jennifer Petkovic; Janet Jull; Manosila Yoganathan; Omar Dewidar; Sarah Baird; Jeremy M Grimshaw; Kjell Arne Johansson; Elizabeth Kristjansson; Jessie McGowan; David Moher; Mark Petticrew; Bjarne Robberstad; Beverley Shea; Peter Tugwell; Jimmy Volmink; George A Wells; Margaret Whitehead; Luis Gabriel Cuervo; Howard White; Monica Taljaard; Vivian Welch Journal: Trials Date: 2020-04-03 Impact factor: 2.279